美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Braveheart Bio

27.45

+0.74002.77%

盤後：27.450.00000.00%16:10 EDT

成交量：55.07萬

成交額：1,518.97萬

市值：24.72億

市盈率：-1.87

高：28.90

開：26.82

低：26.22

收：26.71

52周最高：32.00

52周最低：24.31

股本：9,003.90萬

流通股本：2,583.17萬

量比：2.02

換手率：2.13%

股息：- -

股息率：- -

每股收益(TTM):-14.6845

每股收益(LYR):-17.2003

淨資產收益率：--

總資產收益率：--

市淨率：-25.77

市盈率(LYR):-1.60

資料載入中...

總覽公司新聞資訊公告

美國研究綜述-Adobe、Braveheart Bio、CACI International

新聞稿：Braveheart Bio 宣佈擴大規模首次公開募股完成，並完全行使承銷商超額配股權

市場快訊——美股行情動態-Braveheart Bio、Paysign、Hertz Global

異動解讀 | IPO首日表現強勁，Braveheart Bio盤中大漲67.78%

美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場開盤後股價升逾75%

美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場開盤後股價升逾75%

Braveheart Bio在將IPO規模擴大至3.83億美元后，有望在紐約首秀中股價大漲

生物科技IPO熱潮持續!心血管藥企Braveheart(BRVE.US)募資擴大至3.825億美元，發行價突破指引上限

Braveheart Bio(BRVE.US)IPO定價15-17美元/股，擬募資3億美元推進心血管藥物全球三期臨床

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BRVE/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BRVE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","market":"US","secType":"STK","nameCN":"Braveheart Bio","latestPrice":27.45,"timestamp":1789588800000,"preClose":26.71,"halted":0,"volume":550667,"hourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.45,"latestTime":"16:10 EDT","volume":29198,"amount":801485.1,"timestamp":1789589404708,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02770497940846119,"floatShares":25831738,"shares":90039000,"eps":-14.684527,"marketStatus":"盤後交易","change":0.74,"latestTime":"09-16 19:17:58 EDT","open":26.82,"high":28.9,"low":26.22,"amount":15189732,"amplitude":0.100337,"askPrice":30,"askSize":7,"bidPrice":26.76,"bidSize":5,"shortable":3,"etf":0,"ttmEps":-14.684527,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"listingDate":1785988800000,"exchange":"NASDAQ","adjPreClose":26.71,"postHourTrading":{"tag":"盘后","latestPrice":27.45,"preClose":27.45,"latestTime":"16:10 EDT","volume":29198,"amount":801485.1,"timestamp":1789589404708,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.019471},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BRVE\",,,,,undefined,":{"symbol":"BRVE","floatShares":25831738,"roa":"--","roe":"--","lyrEps":-17.200311,"volumeRatio":2.019471,"shares":90039000,"dividePrice":0,"high":28.9,"amplitude":0.100337,"preClose":26.71,"low":26.22,"week52Low":24.305,"pbRate":"-25.77","week52High":32,"institutionHeld":0,"latestPrice":27.45,"committee":-0.166667,"eps":-14.684527,"divideRate":0,"volume":550667,"delay":0,"ttmEps":-14.684527,"open":26.82,"prevYearClose":18,"prevWeekClose":26.64,"prevMonthClose":25.5,"prevQuarterClose":18,"fiveDayClose":28.91,"twentyDayClose":26.75,"sixtyDayClose":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BRVE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BRVE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BRVE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1788926400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BRVE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BRVE","date":"2026-09-15","current":-1.869315,"percent":0.892857,"low":-23.993466,"twenty":-22.153967,"median":-21.55413,"eighty":-19.825756,"high":-12.297967,"avg":-20.784414,"sd":2.540276,"marketCap":1733844353},"quantilePoints":[{"date":"2026-08-07","current":-22.904964,"twenty":-19.277064,"median":-13.835213,"eighty":-12.912865,"marketCap":1837733965},{"date":"2026-08-14","current":-20.770344,"twenty":-22.55018,"median":-20.842324,"eighty":-16.302149,"marketCap":1666466982},{"date":"2026-08-21","current":-21.930028,"twenty":-22.591769,"median":-21.618113,"eighty":-20.309669,"marketCap":1759511923},{"date":"2026-08-28","current":-22.281932,"twenty":-22.249941,"median":-22.006007,"eighty":-20.827928,"marketCap":1787746250},{"date":"2026-09-04","current":-21.010278,"twenty":-22.169963,"median":-21.930028,"eighty":-20.827928,"marketCap":1685717659},{"date":"2026-09-11","current":-18.437402,"twenty":-22.185958,"median":-21.618113,"eighty":-20.469626,"marketCap":1748603206},{"date":"2026-09-15","current":-18.281784,"twenty":-22.153967,"median":-21.55413,"eighty":-19.825756,"marketCap":1733844353}],"updateTime":1789600678560},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BRVE\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663002003","title":"美國研究綜述-Adobe、Braveheart Bio、CACI International","url":"https://stock-news.laohu8.com/highlight/detail?id=2663002003","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663002003?lang=zh_tw&edition=fundamental","pubTime":"2026-08-31 15:24","pubTimestamp":1788161080,"startTime":"0","endTime":"0","summary":"美国研究综述-Adobe、Braveheart Bio、CACI International路透8月31日-周一，华尔街证券分析师上调了包括Adobe、Braveheart Bio和CACI International在内的几家美国上市公司的评级和目标股价。重点摘要* Adobe IncADBE.O：杰富瑞将目标价从230美元上调至285美元* Braveheart Bio, Inc.BRVE.O：杰富瑞首次覆盖该股，给予“买入”评级* CACI International IncCACI.N：TD Cowen将目标价从550美元上调至700美元以下是路透周一报道的关于美国公司的研究动态摘要。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4S44S0JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B1BXHZ80.USD","LU2458330243.SGD","LU2023250843.SGD","LU0648001328.SGD","LU2065731478.USD","LU0006061336.USD","LU1917777945.USD","LU0868494617.USD","LU1169590202.USD","LU1674673691.USD","ADBE","BK4139","LU0889565833.HKD","LU1878469433.USD","SG9999000418.SGD","LU0477156953.USD","ADBG","BK4585","LU1623119135.USD","BK4533","IE00BQXX3F31.USD","LU0157215616.USD","LU0683600562.USD","LU0006306889.USD","LU1046421795.USD","LU2106854487.HKD","LU0557290698.USD","LU2210149790.SGD","SPAM","LU0949170772.SGD","SG9999015986.USD","BK4534","LU1815333072.USD","IE0031619046.USD","LU0942090050.USD","LU0719512351.SGD","SG9999001424.SGD","LU1069347547.HKD","IE00BYQQ9H92.USD","LU0154245673.USD","IE00B5TLWC47.USD","LU0106261372.USD","LU1633808545.USD","LU0057025933.USD","LU0320765059.SGD","IE0034235188.USD","LU2286300806.USD","LU0868494708.USD","LU0342679015.USD","LU2458330169.SGD","LU0082616367.USD","LU1823568750.SGD","LU0345774631.USD","LU0472753341.HKD","LU0289961442.SGD","LU0314106906.USD","LU1363072403.SGD","BCDF","LU2023250504.SGD","DLTR","SG9999015945.SGD","LU0234572021.USD","LU1506573853.SGD","PTGX","RBRK","LU0980610538.SGD","IE00B66KJ199.SGD","IE00B19Z9505.USD","BK4007","LU2236285917.USD","LU2023251221.USD","LU1084165304.USD","BK4212","LU1035773651.USD","LU1366333091.USD","SG9999015978.USD","SG9999015952.SGD","ADBU","BK4550","SGXZ99366536.SGD","LU0345774391.USD","LU0511384066.AUD","BK4097","HONG","BK4206","LU1261432733.SGD","LU1674673428.USD","LU1712237335.SGD","BK4023","IE00B19Z4B17.USD","LU2095319765.USD","BK4581","LU0109392836.USD","BK4527","LU0011850046.USD","LU0861579265.USD","BK4566","IE00B7SZL793.SGD","LU2237957811.SGD","LU1720051017.SGD","LU0054578231.USD","BK4567","BK4592","LU1974910355.USD","BK4123","LU0154236417.USD","LU2125154935.USD","LU2125154778.USD","SGXZ51526630.SGD","LU1169589451.USD","GB00BDT5M118.USD","BK4006","SGXZ23171101.USD","LU0390134368.USD","LU0957791311.USD","LU0256863902.USD","IE00BQXX3C00.GBP","ICE","BK4114","BRCC","BK4187","LU1153585028.USD","LU0069063385.USD","LU0124676726.USD","LU0072461881.USD","LU1803068979.SGD","LU2237957902.USD","LU0109391861.USD","BRVE","LU0158827948.USD","LU0672654240.SGD","LU0256863811.USD","LU2089284900.SGD","LU1778281490.HKD","IE0009356076.USD","LU0130102774.USD","LU1691799644.USD","LU2360032135.SGD","RSPS","LU0792757196.USD","LU2210150020.SGD","LU0965509101.SGD","LU0708995401.HKD","LU1267930813.SGD","LU1720051108.HKD","BK4543","LU0081259029.USD","LU0738911758.USD","LU0661504455.SGD","LU0061474960.USD","LU0965509283.SGD","LU0348723411.USD","CACI","BK4504","SG9999004303.SGD","LU0130517989.USD","LU1548497426.USD","LU2317271919.USD","BK4613","ATI","LU0314104364.USD","LU0971096721.USD","BK4602","IE00BFXG0V08.USD","LU0889566641.SGD","LU0154245756.USD","LU0234570918.USD","LU0787776722.HKD","LU0170899867.USD","LU1119994496.HKD","LU0289739343.SGD","LU0965509010.AUD","LU1201861249.SGD","HON","BK4155","LU1267930730.SGD","LU0162691827.USD","BK4112","BK4528","LU0689626769.HKD","LU0963586101.USD","PSWD","LU2247934214.USD","LU2357305700.SGD","LU0417517546.SGD","BK4588","LU0198837287.USD","LU2089283258.USD","LU2237438978.USD","SGXZ81514606.USD","LU1235294995.USD","IE00BQXX3D17.EUR","BK4554"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171302218","title":"新聞稿：Braveheart Bio 宣佈擴大規模首次公開募股完成，並完全行使承銷商超額配股權","url":"https://stock-news.laohu8.com/highlight/detail?id=1171302218","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171302218?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:09","pubTimestamp":1786133340,"startTime":"0","endTime":"0","summary":"旧金山，2026年8月7日——Braveheart Bio, Inc.是一家临床阶段的生物制药公司，致力于开发针对肥厚型心肌病及其他严重心血管疾病的下一代疗法。该公司今日宣布，其扩大的首次公开募股已完成。此次发行总计24,437,500股普通股，每股发行价为18.00美元，且承销商已完全行使了购买额外3,187,500股的选择权。所有普通股均由Braveheart Bio提供。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289961442.SGD","BK4533","LU0203345920.USD","BK4567","BRVE","IE000M9KFDE8.USD","MADE","LU0689626769.HKD","BK4585","IPOS","BK4531","LU0069063385.USD","LU2463526074.USD","LU0154245673.USD","LU0472753341.HKD","BK4007","LU0057025933.USD","HCM","BK4588","LU0124676726.USD","LU0289739343.SGD","LU0154245756.USD","BK4149","CMI","LU0511384066.AUD","LU0203347892.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657597666","title":"市場快訊——美股行情動態-Braveheart Bio、Paysign、Hertz Global","url":"https://stock-news.laohu8.com/highlight/detail?id=2657597666","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657597666?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 01:45","pubTimestamp":1786038322,"startTime":"0","endTime":"0","summary":".N美国东部时间13:30，道琼斯工业平均指数.DJI下跌0.85%，报53,886.07点；标普500指数.SPX下跌0.28%，报7,701.81点；纳斯达克综合指数.IXIC下跌0.10%，报26,337.82点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4T44328R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SNDK","FIG","VTRS","LCLN","TPG","PZZA","APP","SRRK","KVUE","CEG","RXO","HWM","CHYM","DDOG","EPAM","LNG","FISV","MAC","KDP","RL","VCTR","WDC","FOUR","ZTS","IOVA","SPCX","BDX","CELH","RDVT","HTZ","PAYC","MRNA","NVAX","PRMB","RCBC","SITM","INSM","BLLN","SRE","ROOT","FRT","MTSI","U","GBFH","UWMC","PH","SMR","BRVE"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1138238457","title":"異動解讀 | IPO首日表現強勁，Braveheart Bio盤中大漲67.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1138238457","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138238457?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:52","pubTimestamp":1786035174,"startTime":"0","endTime":"0","summary":"心血管药物开发商Braveheart Bio今日在纳斯达克首日上市交易，盘中股价大涨67.78%，引发市场广泛关注。Braveheart Bio总部位于加州旧金山，是一家处于临床后期的生物制药公司，专注于开发肥厚型心肌病及其他严重心血管疾病的创新疗法。在2026年生物科技IPO热潮的背景下，Braveheart Bio的成功上市进一步彰显了市场对创新药企的强劲信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656478","title":"美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場 開盤後股價升逾75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656478","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656478?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周四，心血管药企Braveheart Bio(BRVE.US)登陆美股市场，截至发稿，该股涨超75%，报31.405美元。IPO价格为18美元。Braveheart Bio成立于2024年，是一家处于临床后期的生物制药公司，专注于开发肥厚型心肌病(HCM)及其他严重心血管疾病的创新疗法。公司的核心候选药物BHB-1893(亦称HRS-1893)是一种口服小分子心肌肌球蛋白抑制剂，通过特异性抑制心肌肌球蛋白ATP酶活性，使心肌收缩性能正常化，减少左心室肥厚并改善舒张期顺应性。该药物于2025年9月从中国江苏恒瑞医药获得全球(除大中华区外)独家许可授权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"美股异动 | 心血管药企Braveheart Bio(BRVE.US)登陆美股市场 开盘后股价涨超75%","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656475","title":"美股異動 | 心血管藥企Braveheart Bio(BRVE.US)登陸美股市場 開盤後股價升逾75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656475","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656475?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 00:00","pubTimestamp":1786032000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657618658","title":"Braveheart Bio在將IPO規模擴大至3.83億美元后，有望在紐約首秀中股價大漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2657618658","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657618658?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 22:50","pubTimestamp":1786027821,"startTime":"0","endTime":"0","summary":"BUZZ-Braveheart Bio在将IPO规模扩大至3.83亿美元后，有望在纽约首秀中股价大涨8月6日-** 药物开发商Braveheart Bio（BRVE.O）在将美国首次公开募股（IPO）规模扩大至3.825亿美元后，其纳斯达克首日上市开盘价有望高于发行价** 该股最新显示开盘价为每股25美元，高于18美元的发行价** 总部位于加利福尼亚州旧金山的BRVE在规模扩大的首次公开募股（(l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL4T4431TH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSX","LU2750360997.AUD","LU1804176565.USD","LU0106831901.USD","BK4516","LU1868836591.USD","IE0034235188.USD","IE00B19Z3B42.SGD","LU2471134952.CNY","LU2237443549.SGD","LU2750360641.GBP","LU2237443895.HKD","LU0742534661.SGD","LU1791807156.HKD","LU0868494617.USD","LU1868836914.USD","LU2237443978.SGD","LU2471134796.USD","IE0004091025.USD","LU2265009873.SGD","IE00BSNM7G36.USD","LU2237443465.HKD","IE00B19Z3581.USD","LU0345770993.USD","BK4550","BK4127","IE0002270589.USD","LU1894683264.USD","LU2471134879.HKD","LU0048573561.USD","BK4588","LU0942090050.USD","IE0004086264.USD","BRVE","LU0251131958.USD","LU0345770308.USD","LU0868494708.USD","LU1868836757.USD","SF","BK4552","LU0096364046.USD","LU2237443382.USD","BK4585","BK4533","LU1894683348.USD","LU2237443622.USD","LU2237438978.USD","LU2471134523.USD","LU0061475181.USD","LU1668664300.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657070685","title":"生物科技IPO熱潮持續!心血管藥企Braveheart(BRVE.US)募資擴大至3.825億美元，發行價突破指引上限","url":"https://stock-news.laohu8.com/highlight/detail?id=2657070685","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657070685?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 16:28","pubTimestamp":1786004901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IEIH","REDS","BK4127","FRHC","BK4581","MEDX","XBI","GDOC","AGNG","IBBJ","BK4585","LNGR","BK4588","SYNB","IPOS","KCE","BRVE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655330649","title":"Braveheart Bio(BRVE.US)IPO定價15-17美元/股，擬募資3億美元推進心血管藥物全球三期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2655330649","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655330649?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 14:34","pubTimestamp":1785479661,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BRVE","IPOS","UUP","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}